We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Research Reports for Goldman Sachs, Comcast & Abbott Labs
Read MoreHide Full Article
Tuesday, September 20, 2016
Today's Research Daily features new research reports on 16 major stocks, including Abbott Labs (ABT - Free Report) , Comcast (CMCSA - Free Report) and Goldman Sachs (GS - Free Report) .
Shares of Buy ranked Abbott have been under pressure lately, in sympathy with the broader pharma group on political uncertainty about pricing issues (the stock is down more than 6% year-to-date). But the Zacks analyst likes the manner in which the pharma major has been reshaping its portfolio through strategic acquisitions/divestitures. In order to focus on strengths – cardiovascular devices and diagnostics – Abbott has inked a deal to divest its vision care business to J&J. Moreover, the Alere acquisition should boost the diagnostics business, while the St. Jude Medical buyout will complement its cardiovascular devices division and strengthen its long-term growth potential (You can read the full research report on Abbott here>>)
Goldman Sachs shares have come back a bit in recent weeks, but remain in negative territory for the year on persistent macro headwinds for the space as a whole. These issues notwithstanding, the Zacks analyst likes this Buy-ranked stock for its well-diversified business model and industry leading investment banking franchise. The company is also seeking to capitalize on new growth opportunities through several strategic investments including its digital consumer lending platform. Venturing into the ETF market will act as a tailwind, while regulatory approval for its 2016 capital plan demonstrates its financial strength. (You can read the full research report on Goldman Sachs here>>)
Comcast's continued momentum (the stock is up 16% year-to-date) reflects the strength in its Cable business and significant improvement in the NBC Universal segment. Also, Comcast is investing heavily in its theme park business. The company has forayed into the over-the-top video delivery market with the launch of its Internet TV service “Stream”. Comcast’s incorporation of Netflix services into its X1 platform is aimed at checking customer churn and providing viewers with more streaming options and flexibility at breakthrough prices. (You can read the full research report on Comcast here>>)
Today's Long-Term Buys & Sells Today you can gain access to the best long-term trades unearthed by Zacks Research. These moves have double and triple-digit profit potential and are rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>
You can find all of today's stock research reportshere>>
Sheraz Mian
Director of Research
Note: If you want an email notification each time Sheraz publishes a new article, pleaseclick here>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Research Reports for Goldman Sachs, Comcast & Abbott Labs
Tuesday, September 20, 2016
Today's Research Daily features new research reports on 16 major stocks, including Abbott Labs (ABT - Free Report) , Comcast (CMCSA - Free Report) and Goldman Sachs (GS - Free Report) .
Shares of Buy ranked Abbott have been under pressure lately, in sympathy with the broader pharma group on political uncertainty about pricing issues (the stock is down more than 6% year-to-date). But the Zacks analyst likes the manner in which the pharma major has been reshaping its portfolio through strategic acquisitions/divestitures. In order to focus on strengths – cardiovascular devices and diagnostics – Abbott has inked a deal to divest its vision care business to J&J. Moreover, the Alere acquisition should boost the diagnostics business, while the St. Jude Medical buyout will complement its cardiovascular devices division and strengthen its long-term growth potential (You can read the full research report on Abbott here>>)
Goldman Sachs shares have come back a bit in recent weeks, but remain in negative territory for the year on persistent macro headwinds for the space as a whole. These issues notwithstanding, the Zacks analyst likes this Buy-ranked stock for its well-diversified business model and industry leading investment banking franchise. The company is also seeking to capitalize on new growth opportunities through several strategic investments including its digital consumer lending platform. Venturing into the ETF market will act as a tailwind, while regulatory approval for its 2016 capital plan demonstrates its financial strength. (You can read the full research report on Goldman Sachs here>>)
Comcast's continued momentum (the stock is up 16% year-to-date) reflects the strength in its Cable business and significant improvement in the NBC Universal segment. Also, Comcast is investing heavily in its theme park business. The company has forayed into the over-the-top video delivery market with the launch of its Internet TV service “Stream”. Comcast’s incorporation of Netflix services into its X1 platform is aimed at checking customer churn and providing viewers with more streaming options and flexibility at breakthrough prices. (You can read the full research report on Comcast here>>)
Other noteworthy reports we are featuring today include Microsoft (MSFT - Free Report) , Citigroup (C - Free Report) and Philip Morris (PM - Free Report) .
Today's Long-Term Buys & Sells
Today you can gain access to the best long-term trades unearthed by Zacks Research. These moves have double and triple-digit profit potential and are rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>
You can find all of today's stock research reports here>>
Sheraz Mian
Director of Research
Note: If you want an email notification each time Sheraz publishes a new article, please click here>>